MedPath

Rebiotix Inc.

Rebiotix Inc. logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:5

Trial Phases

2 Phases

Phase 2:3
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (60.0%)
Phase 3
2 (40.0%)

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

Phase 3
Completed
Conditions
Infection
Clostridium Difficile Infection
Communicable Diseases
Interventions
First Posted Date
2019-04-30
Last Posted Date
2024-08-07
Lead Sponsor
Rebiotix Inc.
Target Recruit Count
793
Registration Number
NCT03931941
Locations
🇺🇸

Phoenix, Phoenix, Arizona, United States

🇺🇸

North Little Rock, North Little Rock, Arkansas, United States

🇺🇸

Oxnard, Oxnard, California, United States

and more 47 locations

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

Phase 3
Completed
Conditions
Clostridium Difficile Infection (CDI)
Interventions
Drug: Placebo
Drug: Open label RBX2660 (only for confirmed CDI recurrence)
First Posted Date
2017-08-09
Last Posted Date
2024-07-10
Lead Sponsor
Rebiotix Inc.
Target Recruit Count
320
Registration Number
NCT03244644
Locations
🇺🇸

Athens, Athens, Alabama, United States

🇺🇸

Dothan, Dothan, Alabama, United States

🇺🇸

Phoenix, Phoenix, Arizona, United States

and more 59 locations

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

Phase 2
Completed
Conditions
Clostridium Difficile Infection
Interventions
Biological: RBX2660
Drug: Standard of Care Antibiotics
First Posted Date
2015-10-28
Last Posted Date
2021-03-26
Lead Sponsor
Rebiotix Inc.
Target Recruit Count
272
Registration Number
NCT02589847

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

Phase 2
Completed
Conditions
Enterocolitis Clostridium Difficile Recurrent
First Posted Date
2014-11-24
Last Posted Date
2021-01-15
Lead Sponsor
Rebiotix Inc.
Target Recruit Count
150
Registration Number
NCT02299570
Locations
🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

🇺🇸

University of Colorado, Aurora, Colorado, United States

🇺🇸

Borland-Groover Clinic, Jacksonville, Florida, United States

and more 18 locations

Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea

Phase 2
Completed
Conditions
Recurrent Clostridium Difficile Infection
First Posted Date
2013-08-19
Last Posted Date
2019-11-13
Lead Sponsor
Rebiotix Inc.
Target Recruit Count
34
Registration Number
NCT01925417
Locations
🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

🇺🇸

Denver Health and University of Colorado, Denver, Colorado, United States

🇺🇸

Borland-Groover Clinic, Jacksonville, Florida, United States

and more 10 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath